Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors

Transplant International

Volumn 27, Issue 8, 2014, Pages 847-856

  Ruiz San Millán, Juan Carlos ^a   Lõpez Hoyos, Marcos ^a   Segundo, David San ^a   Quintela, Estrella ^a   Rodrigo, Emilio ^a   Gõmez Alamillo, Carlos ^a   Romõn, Iñigo ^a   Arias, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

anti HLA antibodies; calcineurin inhibitors; everolimus; immunosuppression; kidney transplantation; sirolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; HLA ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIZATION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; DONOR; IMMUNOLOGY; KIDNEY TRANSPLANTATION;

CALCINEURIN INHIBITORS; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; TISSUE DONORS; TOR SERINE-THREONINE KINASES;

EID: 84905111920     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12334     Document Type: Article

References (37)

1. Terasaki PI,. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
2. Terasaki PI, Cai J,. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17: 541.
3. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377.
4. Palomar R, Lopez-Hoyos M, Pastor JM, et al,. Impact of HLA antibodies on transplant glomerulopathy. Transplant Proc 2005; 37: 3830.
5. Issa N, Cosio FG, Gloor JM, et al,. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
6. Claas FH,. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 2010; 15: 462.
7. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
8. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al,. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
9. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
10. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
11. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
12. Sellares J, de Freitas DG, Mengel M, et al,. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
13. Montgomery RA, Hardy MA, Jordan SC, et al,. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181.
14. Hernandez D, Sanchez FA, Seron D, et al,. Chronic transplant nephropathy. Nefrologia 2006; 26 (Suppl. 1): 1.
15. Bumbea V, Kamar N, Ribes D, et al,. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517.
16. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
17. Alberu J, Pascoe MD, Campistol JM, et al,. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303.
18. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
19. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
20. Ruiz JC, Campistol JM, Grinyo JM, et al,. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78: 1312.
21. Ruiz JC, Alonso A, Arias M, et al,. Conversion to sirolimus. Nefrologia 2006; 26 (Suppl. 2): 52.
22. + regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550.
23. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al,. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: 3252.
24. Ruiz JC, Sanchez A, Rengel M, et al,. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 2007; 39: 2157.
25. Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, Gomez AC, Calvo RN, Arias M,. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc 2010; 42: 3050.
26. Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, et al,. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 2006; 38: 2424.
27. Sanchez-Fructuoso AI, Ruiz JC, Calvo N, et al,. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors. Transplantation 2012; 93: 398.
28. Tait BD, Susal C, Gebel HM, et al,. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19.
29. Kamar N, Del BA, Congy-Jolivet N, et al,. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013; 27: 455.
30. Everly MJ, Rebellato LM, Haisch CE, et al,. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
31. Stegall MD, Dean PG, Gloor J,. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998.
32. Stegall MD, Raghavaiah S, Gloor JM,. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010; 15: 451.
33. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
34. Cai J, Terasaki PI, Mao Q, et al,. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947.
35. Rebellato LM, Ozawa M, Verbanac KM, Catrou P, Haisch CE, Terasaki PI,. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Clin Transpl 2006; 241.
36. Loupy A, Hill GS, Suberbielle C, et al,. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
37. + T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1643.